Regeneron Pharmaceuticals Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
14,176
- Stock Symbol
-
REGN
- Investments
-
30
- Share Price
-
$687.80
- (As of Tuesday Closing)
Regeneron Pharmaceuticals General Information
Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Contact Information
Website
www.regeneron.comCorporate Office
- 777 Old Saw Mill River Road
- Tarrytown, NY 10591
- United States
Corporate Office
- 777 Old Saw Mill River Road
- Tarrytown, NY 10591
- United States
Regeneron Pharmaceuticals Stock Performance
As of 21-Jan-2025, Regeneron Pharmaceuticals’s stock price is $687.80. Its current market cap is $75.6B with 110M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $687.80 | $681.58 | $666.25 - $1.21K | $75.6B | 110M | 860K | $43.24 |
Regeneron Pharmaceuticals Financials Summary
As of 30-Sep-2024, Regeneron Pharmaceuticals has a trailing 12-month revenue of $13.8B.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 108,777,546 | 88,476,047 | 74,251,057 | 64,826,567 |
| Revenue | 13,847,100 | 13,117,200 | 12,172,900 | 16,071,700 |
| EBITDA | 4,824,900 | 4,197,400 | 5,099,600 | 9,623,500 |
| Net Income | 4,654,500 | 3,953,600 | 4,338,400 | 8,075,300 |
| Total Assets | 37,441,900 | 33,080,200 | 29,214,500 | 25,434,800 |
| Total Debt | 2,704,000 | 2,702,900 | 2,701,400 | 2,699,700 |
Regeneron Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Regeneron Pharmaceuticals Comparisons
Industry
Financing
Details
Regeneron Pharmaceuticals Competitors (65)
One of Regeneron Pharmaceuticals’s 65 competitors is Moderna, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| Seagen | Formerly VC-backed | Bothell, WA | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Biogen | Formerly VC-backed | Cambridge, MA |
Regeneron Pharmaceuticals Patents
Regeneron Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-D1057944-S1 | Retainer adapter assembly | Active | 07-Mar-2024 | ||
| US-20250002992-A1 | Methods of analyzing and characterizing polyadenylation on messenger ribonucleic acid | Pending | 30-Jun-2023 | ||
| US-20250002946-A1 | Methods and compositions for increasing homology-directed repair | Pending | 30-Jun-2023 | ||
| EP-4480491-A1 | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | Pending | 23-Jun-2023 | ||
| JP-2025003405-A | Extended high dose regimen of vegf antagonist for the treatment of intraocular neovascular disease | Pending | 23-Jun-2023 |
Regeneron Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Regeneron Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Regeneron Pharmaceuticals Investments & Acquisitions (30)
Regeneron Pharmaceuticals’s most recent deal was a Later Stage VC with Truveta for . The deal was made on 13-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Truveta | 13-Jan-2025 | Later Stage VC | Enterprise Systems (Healthcare) | ||
| Oxular | 02-Jan-2025 | Merger/Acquisition | Drug Discovery | ||
| Regeneron (1.1 Million Square Foot Industrial Plant in Saratoga Springs Facility) | 27-Sep-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Mammoth Biosciences | 22-Apr-2024 | Later Stage VC | Decision/Risk Analysis | ||
| 2Seventy Bio (Research and Development Pipeline Business) | 01-Apr-2024 | Merger/Acquisition | Biotechnology |
Regeneron Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 23, 2024
18.39 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Regeneron Pharmaceuticals Exits (3)
Regeneron Pharmaceuticals’s most recent exit was on 02-Sep-2019 from Adicet Bio. The exit was categorized as with 15 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Adicet Bio | 02-Sep-2019 | Completed |
|
||
| Intellia Therapeutics | 06-May-2016 | Completed |
|
||
| Adverum Biotechnologies | 31-Jul-2014 | IPO | Completed |
Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Regeneron Ventures | Tarrytown, NY | 2024 | |
| Decibel Therapeutics | Boston, MA | 2015 | |
| Oxular | London, United Kingdom | 2014 |
Regeneron Pharmaceuticals FAQs
-
When was Regeneron Pharmaceuticals founded?
Regeneron Pharmaceuticals was founded in 1988.
-
Where is Regeneron Pharmaceuticals headquartered?
Regeneron Pharmaceuticals is headquartered in Tarrytown, NY.
-
What is the size of Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals has 14,176 total employees.
-
What industry is Regeneron Pharmaceuticals in?
Regeneron Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Regeneron Pharmaceuticals a private or public company?
Regeneron Pharmaceuticals is a Public company.
-
What is Regeneron Pharmaceuticals’s stock symbol?
The ticker symbol for Regeneron Pharmaceuticals is REGN.
-
What is the current stock price of Regeneron Pharmaceuticals?
As of 21-Jan-2025 the stock price of Regeneron Pharmaceuticals is $687.80.
-
What is the current market cap of Regeneron Pharmaceuticals?
The current market capitalization of Regeneron Pharmaceuticals is $75.6B.
-
What is Regeneron Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Regeneron Pharmaceuticals is $13.8B.
-
Who are Regeneron Pharmaceuticals’s competitors?
Moderna, Seagen, Vertex Pharmaceuticals, Intellia Therapeutics, and Biogen are some of the 65 competitors of Regeneron Pharmaceuticals.
-
What is Regeneron Pharmaceuticals’s annual earnings per share (EPS)?
Regeneron Pharmaceuticals’s EPS for 12 months was $43.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
